학술논문
484 - Phase II Study of Mega-Dose 90Y-Ibritumomab Tiuxetan, Fludarabine and Low-Dose TBI Followed By Allogeneic Hematopoietic Transplantation for Relapsed or Refractory Aggressive Large B-Cell Lymphoma: Long-Term Outcomes
Document Type
Abstract
Author
Source
In Transplantation and Cellular Therapy March 2021 27(3) Supplement:S395-S396
Subject
Language
ISSN
2666-6367